Accessibility Menu
 
Propanc Biopharma logo

Propanc Biopharma

(NASDAQ) PPCB

Current Price$0.10
Market Cap$1.63M
Since IPO (2012)-100%
5 Year-100%
1 Year-98%
1 Month-26%

Propanc Biopharma Financials at a Glance

Market Cap

$1.63M

Revenue (TTM)

$29.90K

Net Income (TTM)

$66.07M

EPS (TTM)

$-13.54

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.10

Volume

21,727

Open

$0.10

Previous Close

$0.10

Daily Range

$0.10 - $0.10

52-Week Range

$0.10 - $11.00

PPCB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Propanc Biopharma

Industry

Biotechnology

Employees

2

CEO

James Andrew Nathanielsz

Headquarters

Camberwell, VIC 3124, AU

PPCB Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

-2177%

Net Income Margin

-2209%

Return on Equity

-2100%

Return on Capital

-6%

Return on Assets

-4%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

-1.41%

Stock Overview

Market Cap

$1.63M

Shares Outstanding

15.86M

Volume

21.73K

Short Interest

0.00%

Avg. Volume

2.16M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$57.28M

EBITDA

$58.34M

Operating Cash Flow

$405.17K

Capital Expenditure

$0.00

Free Cash Flow

$405.17K

Cash & ST Invst.

$12.09K

Total Debt

$1.73M

Propanc Biopharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$6.03K

-39.2%

Gross Margin

0.00%

N/A

Market Cap

$1.63M

N/A

Market Cap/Employee

$1.63M

N/A

Employees

1

N/A

Net Income

$3.09M

-618.6%

EBITDA

$3.65M

-1090.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$1.12M

+6.0%

Accounts Receivable

$16.99K

+761.3%

Inventory

$0.00

N/A

Long Term Debt

$1.07M

+1200.3%

Short Term Debt

$613.97K

-45.5%

Return on Assets

-4.37%

N/A

Return on Invested Capital

-5.67%

N/A

Free Cash Flow

$999.14K

-15832.7%

Operating Cash Flow

$999.14K

-15832.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SRBCFSirona Biochem Corp.
$0.01+0.00%
SYGGFSynairgen plc
$0.00+0.00%
GLABFGemina Laboratories Ltd.
$0.05+0.00%
QPTFFQuest PharmaTech Inc.
$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$128.06-0.02%
INTCIntel
$62.38+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.61+0.02%
NOKNokia
$9.46-0.01%

Questions About PPCB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.